PFIZER’s Xeljanz (tofacitinib
citrate) will be listed on the
PBS from 01 Oct as a new
oral treatment alternative for
adults with moderate to severe
rheumatoid arthritis who have
had an inadequate response to
conventional disease-modifying
antirheumatic drugs (DMARDs).The above article was sent to subscribers in Pharmacy Daily's issue from 23 Sep 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Sep 15
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.